Tech Company Financing Transactions
Portola Pharmaceuticals Funding Round
On 11/22/2011, Portola Pharmaceuticals raised $89 million in investment from Temasek Holdings and private investors.
Transaction Overview
Company Name
Announced On
11/22/2011
Transaction Type
Venture Equity
Amount
$89,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds will be used primarily to advance betrixaban, a once-daily, oral Factor Xa inhibitor, through Phase 3 clinical development and to advance development of its companion product, PRT064445, a recombinant Factor Xa inhibitor antidote designed to reverse anticoagulant activity in patients treated with Factor Xa inhibitors suffering major bleeds or requiring surgery. Portola plans to initiate a Phase 3 betrixaban program to prevent venous thromboembolism (VTE) in acute medically ill patients in the first half of 2012.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
270 E. Grand Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Portola Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/22/2011: SoluLink venture capital transaction
Next: 11/22/2011: Marginize venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs